HONG KONG, February 18 /PRNewswire/ --

One of the leading game developers and operators in the PRC, NetDragon Websoft Inc. ("NetDragon" or the "Company", with its subsidiary collectively the "Group"; Stock Code: 8288.HK) is pleased to announce that its new game "Way of the Five" has been honoured by the PRC Ministry of Culture's Examination Committee for Game Content ("the PRC Ministry of Culture") by being included in its third list of "Healthy Online Games for Youngsters."

BIRMINGHAM, England, February 18 /PRNewswire/ --

- A Year of Strong Growth

The Binding Site Limited ("The Binding Site" or the "Company"), a privately owned specialist U.K. diagnostics company, today announces its results for the year ending 30th September 2007.

Financial Highlights:

12 months 12 months % increase % ended 30 ended 30 underlying Sept 2007 Sept 2006 increase at constant GBPMillion GBPMillion currency Revenue 31.1 27.7 12% 18% Freelite(TM) 8.3 5.8 43% 49% sales EBITDA 6.6 4.9 35% 14%

- Underlying sales growth of 18%

- Underlying growth in Freelite(TM) sales of 49%

- 25% growth in North American sales

LONDON, February 16 /PRNewswire/ -- The Royal Pharmaceutical Society of Great Britain (RPSGB) is concerned that Government proposals put forward by Lord Darzi(1) to aggregate local health services into 'polyclinics' or 'super surgeries' could put at risk the public's access to local pharmacies.

Currently 99% of the population can reach a pharmacy by car, walking or public transport within 20 minutes. The RPSGB has recommended strongly to the Department of Health that impact assessments should be mandatory so that local communities are able to understand the effects of any change.

WASHINGTON, February 16 /PRNewswire/ --

- President Praised for Creating PEPFAR; However, Proposed Changes in Priorities Cut Heart from Lifesaving Effort

BOSTON, February 15 /PRNewswire/ --

PAREXEL International Corporation ("PAREXEL") (Nasdaq: PRXL) notes the recent movement in the share price of ClinPhone plc ("ClinPhone" or the "Company"). Under the United Kingdom Takeover Code, PAREXEL confirms that it has made a preliminary proposal to the Board of ClinPhone in relation to a potential offer by PAREXEL for the entire issued and to be issued share capital of ClinPhone. While that preliminary proposal was rejected by the Board of ClinPhone, PAREXEL is currently evaluating its options in relation to ClinPhone. However, there can be no certainty that an offer for ClinPhone will be forthcoming.

Any offer, if made, is likely to be solely in cash. A further announcement will be made in due course.

ROCHESTER, New York, February 15 /PRNewswire/ --

EUSA Pharma (Oxford, UK), a Vaccinex collaboration partner, has announced that it has licensed OP-R003, a human anti-interleukin-6 antibody discovered by Vaccinex, to GlaxoSmithKline.

According to the terms of the product license, GSK will pay an up-front license fee, development milestones, and royalties on product sales to acquire the exclusive world-wide rights to develop and commercialize OP-R003 for the treatment of rheumatoid arthritis and other disease indications. Vaccinex will share 50% of fees, payments and royalties. The antibody was discovered by Vaccinex utilizing its ActivMAb(R) antibody discovery technology and first licensed for co-development by EUSA Pharma (formerly OPi SA).